Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia

被引：26

作者：

Cavalli-Björkman, N

Ösby, E

Lundin, J

Kalin, M

Österborg, A

Gruber, A

机构：

[1] Karolinska Hosp, Dept Hematol & Oncol, SE-17176 Stockholm, Sweden

[2] Karolinska Hosp, Dept Infect Dis, SE-17176 Stockholm, Sweden

来源：

MEDICAL ONCOLOGY | 2002年 / 19卷 / 04期

关键词：

adenovirus; alemtuzumab; Campath-1H; chronic lymphocytic leukemia;

D O I：

10.1385/MO:19:4:277

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Alemtuzumab (Campath-1H) is a humanized CD52 monoclonal antibody that targets normal as well as malignant B- and T-lymphocytes. Alemtuzumab has significant antitumor activity in chronic lymphocytic leukemia (B-CLL) but also induces immunosuppression. We describe a case of fatal adenovirus infection in a heavily pretreated patient with fludarabine-refractory B-CLL receiving alemtuzumab therapy, drawing attention to the fact that also viruses other than cytomegalovirus (CMV) and herpes simplex (HSV) need to be considered in B-CLL patients with fever of unknown origin while on alemtuzumab treatment.

引用

收藏

页码：277 / 280

页数：4

相关论文

共 22 条

[1] Fatal disseminated adenoviral infection in a renal transplant patient [J].

Ardehali, H ;

Volmar, K ;

Roberts, C ;

Forman, M ;

Becker, LC .

TRANSPLANTATION, 2001, 71 (07) :998-999

[2]

Billings J L, 2001, Transpl Infect Dis, V3, P138, DOI 10.1034/j.1399-3062.2001.003003138.x

[3] High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H [J].

Dearden, CE ;

Matutes, E ;

Cazin, B ;

Tjonnfjord, GE ;

Parreira, A ;

Nomdedeu, B ;

Leoni, P ;

Clark, FJ ;

Radia, D ;

Rassam, SMB ;

Roques, T ;

Ketterer, N ;

Brito-Babapulle, V ;

Dyer, MJS ;

Catovsky, D .

BLOOD, 2001, 98 (06) :1721-1726

[4] The implications for childhood leukemia of infection with adenovirus [J].

Dorak, MT .

TRENDS IN MICROBIOLOGY, 1996, 4 (02) :60-63

[5]

Hagberg H, 2001, BLOOD, V98, p806A

[6] ADENOVIRUSES IN THE IMMUNOCOMPROMISED HOST [J].

HIERHOLZER, JC .

CLINICAL MICROBIOLOGY REVIEWS, 1992, 5 (03) :262-274

[7] Adenovirus infections in hematopoietic stem cell transplant recipients [J].

Howard, DS ;

Phillips, GL ;

Reece, DE ;

Munn, RK ;

Henslee-Downey, J ;

Pittard, M ;

Barker, M ;

Pomeroy, C .

CLINICAL INFECTIOUS DISEASES, 1999, 29 (06) :1494-1501

[8] Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study [J].

Keating, MJ ;

Flinn, I ;

Jain, V ;

Binet, JL ;

Hillmen, P ;

Byrd, J ;

Albitar, M ;

Brettman, L ;

Santabarbara, P ;

Wacker, B ;

Rai, KR .

BLOOD, 2002, 99 (10) :3554-3561

[9] Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed [J].

Keating, MJ ;

Cazin, B ;

Coutré, S ;

Birhiray, R ;

Kovacsovics, T ;

Langer, W ;

Leber, B ;

Maughan, T ;

Rai, K ;

Tjonnfjord, G ;

Bekradda, M ;

Itzhaki, M ;

Hérait, P .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :205-213

[10]

KRILOV LR, 1990, REV INFECT DIS, V12, P303